Tyrosine kinase-targeting drugs-associated heart failure.

about

A Review of Matched-pairs Feature Selection Methods for Gene Expression Data Analysis

P2860

Q57147911-8203F8DD-E68C-4E78-BDF7-6897C592C8BA

P2860

Tyrosine kinase-targeting drugs-associated heart failure.

Item

http://www.wikidata.org/entity/Q38401605

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Tyrosine kinase-targeting drugs-associated heart failure.

@en

type

Item

label

Tyrosine kinase-targeting drugs-associated heart failure.

@en

prefLabel

Tyrosine kinase-targeting drugs-associated heart failure.

@en

P1476

Tyrosine kinase-targeting drugs-associated heart failure.

@en

P2093

D R Abernethy

http://www.w3.org/2001/XMLSchema#string

I Lavi

http://www.w3.org/2001/XMLSchema#string

N Gronich

http://www.w3.org/2001/XMLSchema#string

O Barnett-Griness

http://www.w3.org/2001/XMLSchema#string

W Saliba

http://www.w3.org/2001/XMLSchema#string

P2860

An incidence density sampling program for nested case-control analyses

Cancer treatment and survivorship statistics, 2012

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Cardiac dysfunction in the trastuzumab clinical trials experience

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.

Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research.

P2888

bjc.2017.88

P304

1366-1373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2017.88

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Gad Rennert

P577

2017-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084754823

http://www.w3.org/2001/XMLSchema#string

P698

28399109

http://www.w3.org/2001/XMLSchema#string

P932

5482733

http://www.w3.org/2001/XMLSchema#string

Tyrosine kinase-targeting drugs-associated heart failure.

about

P2860

P2860

Tyrosine kinase-targeting drugs-associated heart failure.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932